Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report

Detalhes bibliográficos
Autor(a) principal: da Silva, Douglas Inomata Cardoso [UNESP]
Data de Publicação: 2021
Outros Autores: Santos, Bruna Helena de Oliveira [UNESP], Renosto, Fernanda Lofiego [UNESP], Watanabe, Erika Mayumi [UNESP], Herrerias, Giédre Soares Prates [UNESP], Saad-Hossne, Rogerio [UNESP], Baima, Julio Pinheiro [UNESP], Sassaki, Ligia Yukie [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.12659/AJCR.932963
http://hdl.handle.net/11449/229596
Resumo: Background: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population.
id UNSP_6fed838765374a5dd92c1dc0847931d4
oai_identifier_str oai:repositorio.unesp.br:11449/229596
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case reportAdalimumabCrohn DiseaseInflammatory Bowel DiseasesLatent TuberculosisBackground: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population.Department of Internal Medicine São Paulo State University (UNESP) Medical SchoolDepartment of Radiology São Paulo State University (UNESP) Medical SchoolDepartment of Surgery São Paulo State University (UNESP) Medical SchoolDepartment of Internal Medicine São Paulo State University (UNESP) Medical SchoolDepartment of Radiology São Paulo State University (UNESP) Medical SchoolDepartment of Surgery São Paulo State University (UNESP) Medical SchoolUniversidade Estadual Paulista (UNESP)da Silva, Douglas Inomata Cardoso [UNESP]Santos, Bruna Helena de Oliveira [UNESP]Renosto, Fernanda Lofiego [UNESP]Watanabe, Erika Mayumi [UNESP]Herrerias, Giédre Soares Prates [UNESP]Saad-Hossne, Rogerio [UNESP]Baima, Julio Pinheiro [UNESP]Sassaki, Ligia Yukie [UNESP]2022-04-29T08:33:21Z2022-04-29T08:33:21Z2021-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.12659/AJCR.932963American Journal of Case Reports, v. 22, n. 1, 2021.1941-5923http://hdl.handle.net/11449/22959610.12659/AJCR.9329632-s2.0-85115806846Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAmerican Journal of Case Reportsinfo:eu-repo/semantics/openAccess2024-08-14T17:23:00Zoai:repositorio.unesp.br:11449/229596Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:23Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
title Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
spellingShingle Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
da Silva, Douglas Inomata Cardoso [UNESP]
Adalimumab
Crohn Disease
Inflammatory Bowel Diseases
Latent Tuberculosis
title_short Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
title_full Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
title_fullStr Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
title_full_unstemmed Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
title_sort Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
author da Silva, Douglas Inomata Cardoso [UNESP]
author_facet da Silva, Douglas Inomata Cardoso [UNESP]
Santos, Bruna Helena de Oliveira [UNESP]
Renosto, Fernanda Lofiego [UNESP]
Watanabe, Erika Mayumi [UNESP]
Herrerias, Giédre Soares Prates [UNESP]
Saad-Hossne, Rogerio [UNESP]
Baima, Julio Pinheiro [UNESP]
Sassaki, Ligia Yukie [UNESP]
author_role author
author2 Santos, Bruna Helena de Oliveira [UNESP]
Renosto, Fernanda Lofiego [UNESP]
Watanabe, Erika Mayumi [UNESP]
Herrerias, Giédre Soares Prates [UNESP]
Saad-Hossne, Rogerio [UNESP]
Baima, Julio Pinheiro [UNESP]
Sassaki, Ligia Yukie [UNESP]
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv da Silva, Douglas Inomata Cardoso [UNESP]
Santos, Bruna Helena de Oliveira [UNESP]
Renosto, Fernanda Lofiego [UNESP]
Watanabe, Erika Mayumi [UNESP]
Herrerias, Giédre Soares Prates [UNESP]
Saad-Hossne, Rogerio [UNESP]
Baima, Julio Pinheiro [UNESP]
Sassaki, Ligia Yukie [UNESP]
dc.subject.por.fl_str_mv Adalimumab
Crohn Disease
Inflammatory Bowel Diseases
Latent Tuberculosis
topic Adalimumab
Crohn Disease
Inflammatory Bowel Diseases
Latent Tuberculosis
description Background: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-01
2022-04-29T08:33:21Z
2022-04-29T08:33:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.12659/AJCR.932963
American Journal of Case Reports, v. 22, n. 1, 2021.
1941-5923
http://hdl.handle.net/11449/229596
10.12659/AJCR.932963
2-s2.0-85115806846
url http://dx.doi.org/10.12659/AJCR.932963
http://hdl.handle.net/11449/229596
identifier_str_mv American Journal of Case Reports, v. 22, n. 1, 2021.
1941-5923
10.12659/AJCR.932963
2-s2.0-85115806846
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv American Journal of Case Reports
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128146395889664